NASDAQ
Adaptive Biotechnologies Corporation (ADPT) reported revenue of $276.98M and net income of $-59.50M for FY 2025. The gross profit margin is 74.2% with a net profit margin of -21.5%.
Financial data for ADPT
54.77% YoY
62.69% YoY
63.89% YoY
Annual Income Statement for ADPT
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $277M | $179M | $170M | $185M | $154M |
| Cost of Revenue | $71M | $72M | $76M | $58M | $49M |
| Gross Profit | $206M | $107M | $95M | $127M | $105M |
| Operating Expenses | $263M | $269M | $322M | $328M | $314M |
| Operating Income | -$57M | -$163M | -$227M | -$200M | -$209M |
| Net Income | -$59M | -$159M | -$225M | -$200M | -$207M |
| EPS | $-0.39 | $-1.08 | $-1.56 | $-1.00 | $-1.46 |
| EBITDA | -$30M | -$129M | -$189M | -$175M | -$193M |
No price data available for this timeframe.